Why we don't have an HIV vaccine, and how we can develop one

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1642-1654

  Harris, Jeffrey E ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Blackstone Valley Community Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VAXGEN;

CONFERENCE PAPER; DRUG DESIGN; DRUG RESEARCH; ECONOMIC ASPECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INVESTMENT; NONHUMAN; RISK ASSESSMENT; VACCINATION;

AIDS VACCINES; DRUG DISCOVERY; DRUG INDUSTRY; HIV INFECTIONS; HUMANS; RESEARCH SUPPORT AS TOPIC;

EID: 77952226221     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1642     Document Type: Conference Paper

References (51)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654-65.
2. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et at. Randomized double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J Infect Dis. 2006;194(12):1661-71.
3. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et at. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008;372(9653):1894-905.
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind randomised placebo-controlled test-of-concept trial. Lancet. 2008;372(9653):1881-93.
5. Baltimore D. Presidential address. A global perspective on science and technology. Science. 2008;322(5901):544-51.
6. Global Solutions for Infectious Diseases [Internet]. South San Francisco (CA): GSID; c2009. Press release, Prime-boost vaccine study shows modest effect in preventing HIV; 2009 Sep 24 [cited 2009 Oct 1]. Available from: http://www.gsid.org/downloads/GSIDRV144-Press-Release.pdf
7. Schoenly KA, Weiner DB. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business." J Virol. 2008;82(7):3166-80.
8. Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med. 2005;2(2):e25.
9. International AIDS Vaccine Initiative. AIDS vaccine blueprint 2006: actions to strengthen global research and development. New York (NY): IAVI; 2006.
10. Bernstein A. An HIV/AIDS vaccine: where do we go from here? Trends Microbiol. 2008;16(12):553-4.
11. Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS. 2008;22 Suppl 1:S67-74.
12. HIV Vaccines and Microbicides Resource Tracking Working Group. Adapting to realities: trends in HIV prevention research funding, 2000-2008 [Internet]. New York (NY): Working Group; 2009 [cited 2009 Oct 1]. Available from: http://hivvresourcetracking.org/downloads/Adapting-to-Realities.July.2009.pdf
13. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251-61.
14. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3(1):e1474.
15. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359(5):463-72.
16. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One. 2008;3(11):e3784.
17. Stephenson J. HIV studies: progress in microbicides, dead end for an immune-boosting strategy. JAMA. 2009;301(14):1421-2.
18. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised double-blind, placebo-controlled trial. Lancet. 2008;371(9630):2109-19.
19. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358(15):1560-71.
20. Auvert B, Marseille E, Korenromp EL, Lloyd-Smith J, Sitta R, Taljaard D, et al. Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in sub-Saharan Africa. PLoS One. 2008;3(8):e2679.
21. AIDS Vaccine Advocacy Coalition (AVAC). Ongoing and planned ARV-based prevention (PrEP) trials - June 2009. New York (NY): PrEP Watch; 2009.
22. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806-15.
23. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et aL Public health: reassessing HIV prevention. Science. 2008;320(5877):749-50.
24. International AIDS Vaccine Initiative. Forecasting the global demand for a preventive AIDS vaccine. New York (NY): IAVI; 2007.
25. International AIDS Vaccine Initiative. Procurement and pricing of new vaccines for developing countries. New York (NY): IAVI; 2008.
26. Berndt ER, Glennerster R, Kroner MR, Lee J, Levine R, Weizsacker G, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ. 2007;16(5):491-511.
27. International AIDS Vaccine Initiative. Innovative financing mechanisms to advance global health. IAVI insights. New York (NY): IAVI; 2009 Jun.
28. Steinbrook R. Thailand and the compulsory licensing of efavirenz. N Engl J Med 2007;356(6):544-6.
29. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 2007;4(12):e348.
30. Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008;320(5877):760-4.
31. VaxGen Inc. SEC form 10Q for the quarterly period ending June 30, 2002. South San Francisco (CA): VaxGen; 2002 Aug 14.
32. HIV Vaccine Trials Network [Internet]. Seattle (WA): HVTN. Press release, HVTN, partners review Phase II trial data; 2002 Feb 25 [cited 2009 Sep 21]. Available from: http://www.hvtn.org/media/press-releases.sht?id=20
33. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis. 2005;191(5):666-77.
34. VaxGen Inc. SEC form 10-Q for the quarterly period ending March 31, 2009. South San Francisco (CA): VaxGen; 2009.
35. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009;15(8):901-6.
36. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;Sep 3. E-pub ahead of print.
37. Letvin NL. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity. 2007;27(3):366-9.
38. South African AIDS Vaccine Initiative. Update on the STEP and Phambili HIV vaccine trials [Internet]. Cape Town (South Africa): SAAVI; 2007 Oct 23 [cited 2009 Oct 1]. Available from: http://www.phambili.org.za/press/ SAAVIrelease23October2007.pdf
39. National Institute of Allergy and Infectious Diseases [Internet]. Bethesda (MD): NIAID; c2009. Press release, NIAID will not move forward with the PAVE 100 HIV vaccine trial; 2008 Jul 17 [cited 2009 Sep 21]. Available from: http://ww3.niaid.nih.gov/news/newsreleases/2008/pave100.htm
40. Merck and Co. Inc. SEC form 10-K for the fiscal year ended December 31, 2007. Whitehouse Station (NJ): Merck and Co.; 2008 Feb 28.
41. Merck and Co. Inc. SEC form 10-K for the fiscal year ended December 31, 2008. Whitehouse Station (NJ): Merck and Co.; 2009 Feb 27.
42. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008;4(6):449-52.
43. AIDS Vaccine Advocacy Coalition. What is the FEM-PrEP clinical trial? FEM-PrEP Trial Update, Issue no. 1. New York (NY): PrEP Watch; 2009 [cited 2009 Sep 21]. Available from: http://www.prepwatch.org/pdf/Trials/FEMPrEP-Issue%201- Jan2009.pdf
44. Kremer M, Snyder CM. Why is there no AIDS vaccine? Cambridge (MA): Harvard University Department of Economics; 2006. Working paper.
45. Coase RH. The problem of social cost. J Law Econ. 1960;3(1):1-44.
46. Warkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008;14(6):617-21.
47. Institute of Medicine. Methodological challenges in biomedical HIV prevention trials. Washington (DC): National Academies Press; 2008.
48. Buchbinder S. Exploring hypotheses for differential HIV acquisition rates [Internet]. Paper presented at: November 2007 HVTN conference: open scientific session on the STEP data; 2007 Nov. Available from: http://www.hvtn.org/fgm/ 1107slides/Buchbinder.pdf
49. International AIDS Vaccine Initiative. Promoting innovation and access through effective management of intellectual property (background). New York (NY): IAVI; 2008.
50. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK. AIDS/HIV. A STEP into darkness or light? Science. 2008;320(5877)753-5.
51. Institute of Medicine. Confronting AIDS: directions for public health, health care, and research. Washington (DC): National Academies Press; 1986.